Benign prostatic hyperplasia
Conditions
Interventions
the intake of naftopidil
Sponsors
Department of Urology Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: The inclusion criteria were as follows: Total International Prostate Symptom Score (IPSS) > 8; IPSS-QOL score > 3; total OAB symptom scores (OABSS) > 3; urinary urgency episodes> 1 per week; prostate volume > 25 mL as determined based on transabdominal ultrasonography; maximum urinary flow rate (Qmax) < 15 mL/sec at voided volume of > 100 mL; and residual urine < 150 mL; age > 50 years.
Exclusion criteria
Exclusion criteria: Patients were excluded if they received oral treatment with alpha1-blockers, anticholinergic agents, 5-alpha reductase inhibitor (5-ARI), antidepressants, anti-anxiety agents, or sex hormonal agents; had neurogenic bladder dysfunction, bladder calculi, or active urinary tract infection; and had severe cardiac disease, renal dysfunction (serum creatinine level > 2 mg/dL), and hepatic dysfunction (aspartate and alanine aminotransferase concentrations more than twice the normal values).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the improvement of overactive bladder by escalating the dose of naftopidilfor patients with benign prostatic enlargement complicated by overactive bladder | — |
Countries
Japan
Contacts
Public ContactMatsukawa Yoshihisa
Nagoya University Graduate School of Medicine Department of Urology
Outcome results
None listed